Pathophysiological mechanism of bone loss in type 2 diabetes involves inverse regulation of osteoblast function by pgc-1a and skeletal muscle atrogenes: Adipor1 as a potential target for reversing diabetes-induced osteopenia

Diabetes

Volumn 64, Issue 7, 2015, Pages 2609-2623

  Khan, Mohd Parvez ^a   Kumar Singh, Abhishek ^a   Joharapurkar, Amit Arvind ^b   Yadav, Manisha ^a   Shree, Sonal ^a   Kumar, Harish ^a   Gurjar, Anagha ^a   Mishra, Jay Sharan ^a   Tiwari, Mahesh Chandra ^a   Kumar Nagar, Geet ^a   Kumar, Sudhir ^a   Ramachandran, Ravishankar ^a   Sharan, Anupam ^c   Jain, Mukul Rameshchandra ^b   Kumar Trivedi, Arun ^a   Maurya, Rakesh ^a   Godbole, Madan Madhav ^d   Gayen, Jiaur Rahaman ^a   Sanyal, Sabyasachi ^a   Chattopadhyay, Naibedya ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b ZYDUS RESEARCH CENTRE   (India)

^c Vinayak Cosmetic Surgery and Laser Centre   (India)

^d SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

6 C BETA DEXTRO GLUCOPYRANOSYL 5,7,3',4' TETRAHYDROXYDIHYDROFLAVONOL; ADIPONECTIN RECEPTOR 1; FATTY ACID; FLAVONOL DERIVATIVE; LEPTIN RECEPTOR; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PIOGLITAZONE; UNCLASSIFIED DRUG; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 1, MOUSE; MUSCLE PROTEIN; PPARGC1A PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MASS; CONTROLLED STUDY; CORTICAL BONE; DRUG TARGETING; GLUCOTOXICITY; HUMAN; LIPOTOXICITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPENIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SKELETAL MUSCLE; TRABECULAR BONE; UPREGULATION; WILD TYPE; AGONISTS; ANIMAL; BONE DENSITY; BONE DISEASES, METABOLIC; C57BL MOUSE; COMPLICATION; GENETICS; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY;

ANIMALS; BONE DENSITY; BONE DISEASES, METABOLIC; DIABETES MELLITUS, TYPE 2; INSULIN RESISTANCE; MICE; MICE, INBRED C57BL; MUSCLE PROTEINS; MUSCLE, SKELETAL; OSTEOBLASTS; RECEPTORS, ADIPONECTIN; TRANSCRIPTION FACTORS;

EID: 84962081629     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1611     Document Type: Article

References (61)

1. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166: 495-505
2. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: The Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006;91:3404-3410
3. Kilpadi KL, Eldabaje R, Schmitz JE, et al. Type 2 diabetes is associated with vertebral fractures in a sample of clinic-and hospital-based Latinos. J Immigr Minor Health 2014;16:440-449
4. Viégas M, Costa C, Lopes A, Griz L, Medeiro MA, Bandeira F. Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. J Diabetes Complications 2011;25:216-221
5. Schwartz AV, Vittinghoff E, Bauer DC, et al.; Study of Osteoporotic Fractures (SOF) Research Group; Osteoporotic Fractures in Men (MrOS) Research Group; Health, Aging, and Body Composition (Health ABC) Research Group. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011;305:2184-2192
6. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res 2009;24:702-709
7. Hernandez RK, Do TP, Critchlow CW, Dent RE, Jick SS. Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. Acta Orthop 2012;83:653-660
8. Gooch HL, Hale JE, Fujioka H, Balian G, Hurwitz SR. Alterations of cartilage and collagen expression during fracture healing in experimental diabetes. Connect Tissue Res 2000;41:81-91
9. Topping RE, Bolander ME, Balian G. Type X collagen in fracture callus and the effects of experimental diabetes. Clin Orthop Relat Res 1994;308:220-228
10. Schwartz AV, Garnero P, Hillier TA, et al.; Health, Aging, and Body Composition Study. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009;94:2380-2386
11. Farr JN, Drake MT, Amin S, Melton LJ 3rd, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 2014;29:787-795
12. Patsch JM, Burghardt AJ, Yap SP, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res 2013; 28:313-324
13. Fajardo RJ, Karim L, Calley VI, Bouxsein ML. A review of rodent models of type 2 diabetic skeletal fragility. J Bone Miner Res 2014;29:1025-1040
14. Orland MJ, Permutt MA. Quantitative analysis of pancreatic proinsulin mRNA in genetically diabetic (db/db) mice. Diabetes 1987;36:341-347
15. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M; Consensus Workshop Group. Type 2 diabetes in the young: The evolving epidemic: The international diabetes federation consensus workshop. Diabetes Care 2004; 27:1798-1811
16. Song SH, Hardisty CA. Early-onset Type 2 diabetes mellitus: An increasing phenomenon of elevated cardiovascular risk. Expert Rev Cardiovasc Ther 2008;6: 315-322
17. Zeitler P, Hirst K, Pyle L, et al.; TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366:2247-2256
18. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005;146:693-700
19. Polonsky KS. Lilly Lecture 1994. The beta-cell in diabetes: From molecular genetics to clinical research. Diabetes 1995;44:705-717
20. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345:971-980
21. Giuffrida FM, Reis AF. Genetic and clinical characteristics of maturity-onset diabetes of the young. Diabetes Obes Metab 2005;7:318-326
22. Pollock NK, Bernard PJ, Wenger K, et al. Lower bone mass in prepubertal overweight children with prediabetes. J Bone Miner Res 2010;25: 2760-2769
23. Sharan K, Mishra JS, Swarnkar G, et al. A novel quercetin analogue from a medicinal plant promotes peak bone mass achievement and bone healing after injury and exerts an anabolic effect on osteoporotic bone: The role of aryl hydrocarbon receptor as a mediator of osteogenic action. J Bone Miner Res 2011; 26:2096-2111
24. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-661
25. Khan K, Singh A, Mittal M, et al. [6]-Gingerol induces bone loss in ovary intact adult mice and augments osteoclast function via the transient receptor potential vanilloid 1 channel. Mol Nutr Food Res 2012;56:1860-1873
26. Swarnkar G, Sharan K, Siddiqui JA, et al. A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts. Br J Pharmacol 2012;165:1526-1542
27. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using microcomputed tomography. J Bone Miner Res 2010;25:1468-1486
28. Srivastava K, Khan K, Tyagi AM, et al. Greater skeletal gains in ovary intact rats at maturity are achieved by supplementing a standardized extract of Butea monosperma stem bark that confers better bone conserving effect following ovariectomy and concurrent treatment withdrawal. Evid Based Complement Alternat Med 2013;2013:519387
29. Gautam AK, Bhargavan B, Tyagi AM, et al. Differential effects of formononetin and cladrin on osteoblast function, peak bone mass achievement and bioavailability in rats. J Nutr Biochem 2011;22:318-327
30. Wong GL. Basal activities and hormone responsiveness of osteoclast-like and osteoblast-like bone cells are regulated by glucocorticoids. J Biol Chem 1979;254:6337-6340
31. Maniatopoulos C, Sodek J, Melcher AH. Bone formation in vitro by stromal cells obtained from bone marrow of young adult rats. Cell Tissue Res 1988;254: 317-330
32. Singh AK, Joharapurkar AA, Khan MP, et al. Orally active osteoanabolic agent 6GTDF binds to adiponectin receptors, with a preference for AdipoR1, induces adiponectin-associated signaling and improves metabolic health in a rodent model of diabetes. Diabetes 2014;63:3530-3544
33. Khan MP, Mishra JS, Sharan K, et al. A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: A comparative study with human parathyroid hormone. Phytomedicine 2013;20:1256-1266
34. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000; 108:153-164
35. Miller SC, De Saint-Georges L, Bowman BM, Jee WS. Bone lining cells: Structure and function. Scanning Microsc 1989;3:953-960; discussion 960-961
36. Williams GA, Callon KE, Watson M, et al. Skeletal phenotype of the leptin receptor-deficient db/db mouse. J Bone Miner Res 2011;26:1698-1709
37. Harrity T, Farrelly D, Tieman A, et al. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Diabetes 2006;55:240-248
38. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946
39. Liang H, Ward WF. PGC-1alpha: A key regulator of energy metabolism. Adv Physiol Educ 2006;30:145-151
40. Coll T, Jové M, Rodríguez-Calvo R, et al. Palmitate-mediated downregulation of peroxisome proliferator-activated receptor-g coactivator 1a in skeletal muscle cells involves MEK1/2 and nuclear factor-kB activation. Diabetes 2006;55:2779-2787
41. Nervina JM, Magyar CE, Pirih FQ, Tetradis S. PGC-1alpha is induced by parathyroid hormone and coactivates Nurr1-mediated promoter activity in osteoblasts. Bone 2006;39:1018-1025
42. Chen CT, Shih YR, Kuo TK, Lee OK, Wei YH. Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells. Stem Cells 2008;26:960-968
43. Akhmedov D, Berdeaux R. The effects of obesity on skeletal muscle regeneration. Front Physiol 2013;4:371
44. Sandri M, Lin J, Handschin C, et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A 2006;103:16260-16265
45. Kondo H, Ezura Y, Nakamoto T, et al. MURF1 deficiency suppresses unloading-induced effects on osteoblasts and osteoclasts to lead to bone loss. J Cell Biochem 2011;112:3525-3530
46. Potts W, Bowyer J, Jones H, et al. Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy. Int J Exp Pathol 2004;85:85-96
47. Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature 2010; 464:1313-1319
48. Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond) 2008;32(Suppl. 7):S13-S18
49. Lustig Y, Barhod E, Ashwal-Fluss R, et al. RNA-binding protein PTB and microRNA-221 coregulate AdipoR1 translation and adiponectin signaling. Diabetes 2014;63:433-445
50. Lin YY, Chen CY, Chuang TY, et al. Adiponectin receptor 1 regulates bone formation and osteoblast differentiation by GSK-3b/b-catenin signaling in mice. Bone 2014;64:147-154
51. Molinuevo MS, Schurman L, McCarthy AD, et al. Effect of metformin on bone marrow progenitor cell differentiation: In vivo and in vitro studies. J Bone Miner Res 2010;25:211-221
52. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 2008;375:414-419
53. Davis RC, Castellani LW, Hosseini M, et al. Early hepatic insulin resistance precedes the onset of diabetes in obese C57BLKS-db/db mice. Diabetes 2010; 59:1616-1625
54. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 2000;100: 197-207
55. Díaz-López A, Bulló M, Juanola-Falgarona M, et al. Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: A nested case-control study. J Clin Endocrinol Metab 2013;98:4524-4531
56. Wang X, Kua HY, Hu Y, et al. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol 2006;172:115-125
57. Shinoda Y, Yamaguchi M, Ogata N, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006;99:196-208
58. Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005;331:520-526
59. Jang WG, Kim EJ, Bae IH, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone 2011; 48:885-893
60. Shao X, Cao X, Song G, Zhao Y, Shi B. Metformin rescues the MG63 osteoblasts against the effect of high glucose on proliferation. J Diabetes Res 2014; 2014:453940
61. Kim JE, Ahn MW, Baek SH, et al. AMPK activator, AICAR, inhibits palmitateinduced apoptosis in osteoblast. Bone 2008;43:394-404